Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence.
- Authors
- Benyamina, Amine; Lecacheux, Marie; Blecha, Lisa; Reynaud, Michel; Lukasiewcz, Michael
- Year
- 2008
- Journal
- Expert review of neurotherapeutics
- PMID
- 18345976
- DOI
- 10.1586/14737175.8.3.479
Cannabis has long been perceived as a drug causing questionable dependence. Only recently has a clinically recognized withdrawal syndrome been described, thus laying the foundations for specific treatment evaluations. Six different pharmacotherapies have been studied in cannabis withdrawal. Of these, only oral tetrahydrocannabinol, and perhaps mirtazapine, have shown some promise in the specific treatment of withdrawal symptoms. In cannabis dependence, rimonabant, and perhaps buspiron, have shown promising results. Clinical trials of oral tetrahydrocannabinol were less convincing. Cognitive and behavioral therapies and motivational enhancement therapies have proven their efficacy in several randomized controlled trials. Brief therapies have also been associated with good compliance and efficacy. Combinations with voucher incentives in certain populations have been associated with improved treatment compliance and reduced cannabis use. Only two studies have analyzed the cost-efficacy of psychotherapies. It would seem that brief combined cognitive and behavioral therapies, and motivational enhancement therapies are the most cost effective. For the moment, it is uncertain whether the additional treatment costs associated with voucher incentives are proportional to the accrued abstinence duration.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Pharmacotherapies for cannabis use disorder: A systematic review and network meta-analysis. | Bahji A et al. | — | 2021 | → |
| Pharmacotherapies for cannabis dependence. | Nielsen S et al. | — | 2019 | → |
| The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. | Schlienz NJ et al. | — | 2018 | → |
| Cannabis Withdrawal: A Review of Neurobiological Mechanisms and Sex Differences. | Schlienz NJ et al. | — | 2017 | → |
| Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review. | Copeland J et al. | — | 2016 | → |
| Anxiety and substance use disorders: co-occurrence and clinical issues. | Vorspan F et al. | — | 2015 | → |
| Risks associated with the non-medicinal use of cannabis. | Hoch E et al. | — | 2015 | → |
| Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users. | Herrmann ES et al. | — | 2015 | → |
| Trajectories of marijuana use from adolescence to adulthood predicting unemployment in the mid 30s. | Lee JY et al. | — | 2015 | → |
| Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum. | Bonnet U et al. | — | 2014 | → |
| Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. | McClure EA et al. | — | 2014 | → |
| Pharmacotherapies for cannabis dependence. | Marshall K et al. | — | 2014 | → |
| Feasibility and impact of brief interventions for frequent cannabis users in Canada. | Fischer B et al. | — | 2013 | → |
| Internet and computer based interventions for cannabis use: a meta-analysis. | Tait RJ et al. | — | 2013 | → |
| Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice. | Aracil-Fernández A et al. | — | 2013 | → |
| Project reduce: reducing alcohol and marijuana misuse: effects of a brief intervention in the emergency department. | Woolard R et al. | — | 2013 | → |
| The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. | Vandrey R et al. | — | 2013 | → |
| Case series of perimenopausal women with insomnia treated with mirtazapine followed by prolonged-release melatonin add-on and monotherapy. | Dolev Z | — | 2011 | → |
| Effects of chronic, heavy cannabis use on executive functions. | Crean RD et al. | — | 2011 | → |
| Pharmacological treatment of cannabis dependence. | Weinstein AM et al. | — | 2011 | → |
| Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. | Vandrey R et al. | — | 2011 | → |
| [Pharmacological and psychosocial interventions for cannabis use disorders]. | Budney AJ et al. | — | 2010 | → |
| Pharmacotherapies for adolescent substance use disorders. | Simkin DR et al. | — | 2010 | → |
| The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review. | Crunelle CL et al. | — | 2010 | → |
| Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. | Agrawal A et al. | — | 2009 | → |
| Pharmacotherapy for cannabis dependence: how close are we? | Vandrey R et al. | — | 2009 | → |
| Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome. | Kapoor S | — | 2009 | → |
| Novel medications to treat addictive disorders. | Montoya ID et al. | — | 2008 | → |